Overview of precautions when using LARTRUVO

When usingLARTRUVO, patients and medical staff need to pay special attention to the following points to ensure the safety and effectiveness of the treatment:

Allergic Reactions:LARTRUVO may cause allergic reactions, especially during the first dose. There is a higher risk of severe allergic reactions (such as shortness of breath, rash, throat swelling, etc.). Emergency preparations should be made during treatment and the patient's vital signs should be monitored.

Heart Health: Olaratumab may have effects on heart function, especially when used in combination with chemotherapy drugs. Patients should undergo electrocardiogram examination during treatment to observe whether there is abnormal cardiac function.

Liver function monitoring: Use of olaratumab may result in elevated liver enzymes, so liver function needs to be checked regularly. If the patient develops symptoms such as jaundice, fatigue, nausea, etc., the treatment plan needs to be adjusted in time.

Immune system suppression:LARTRUVOmay cause a decrease in white blood cells and platelets, leading to decreased immune system function and an increased risk of bleeding. Patients should seek medical attention promptly if signs of infection or bleeding occur.

Pregnancy and Breastfeeding: Pregnant women should avoid using this drug because of its potential harmful effects on the fetus. During treatment, it is recommended to use effective contraceptive measures. It is not clear whether it is suitable for nursing mothers, so it is recommended to stop using it during breastfeeding or stop taking the drug before breastfeeding.

Renal Impairment: In patients with a history of kidney disease, special caution should be taken to monitor kidney function regularly.

LARTRUVO is an effective anti-tumor drug, but due to the possibility of a series of side effects, patients should strictly follow the doctor's instructions during treatment and undergo various examinations regularly to ensure that the treatment is safe and effective.

Reference materials:https://www.drugs.com/cdi/olaratumab.html